Observational studyThe Journal of antimicrobial chemotherapy2026

'Leaving no stones unturned': up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort.

Arturo Ciccullo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.